相关实验视频

Updated: May 25, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

布列维的临床药理学:专注于已知和潜在的药物相互作用

Martina Billi¹, Sara Soloperto¹, Stefano Bonora¹

¹Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, C.so Svizzera 164, 10149 Turin, Italy.

|February 26, 2025

概括

抗肝炎D病毒 (HDV) 药物布莱维尔提德 (BLV) 具有较低的药物相互作用潜力,特别是在标准剂量2毫克/天时. 建议在与影响NTCP的药物同时使用时谨慎使用.

科学领域:

肝病学肝病学是一种肝病学.
病毒学病毒学
药理学药理学是指药理学的学科.

背景情况:

肝炎D病毒 (HDV) 是一种缺陷的病毒,需要与乙型肝炎病毒 (HBV) 共同感染.
布列维尔提德 (BLV) 是第一类针对高强度病毒的药物,通过抑制其与NTCP的结合.
关于BLV的药理动力学/药理动力学 (PK/PD) 和药物相互作用 (DDI) 概况的数据有限.

研究的目的:

系统地审查目前关于BLV.LV的PK/PD和DDI配置文件的知识.
评估实验测试的相互作用和相互作用的假设机制.
专注于与同时使用的抗感染药物和影响NTCP的药物相互作用.

主要方法:

来自PubMed和EMA的BLV的PK,PD和DDI数据的文献综述.
在体内和体外相互作用研究的评估.
基于NTCP,CYP和ABC载体等药物点的潜在相互作用的评估.

主要成果:

由于目标介导药物处置,BLV表现出非线性PK.
活体研究显示没有临床相关的DDI;高剂量表明CYP3A4抑制较弱.
在体外研究表明,在超治疗度下,OATP载体抑制较弱.

结论:

在批准的2毫克/天剂量下,BLV的DDI潜力通常很低.
与影响NTCP的药物同时使用需要仔细考虑.
BLV不是CYP和ABC载体的基质,这表明通过这些通路的相互作用风险有限.

关键词:

布莱维尔提德 (Hepcludex®,Myrcludex-B) 的使用情况药物药物相互作用乙型肝炎病毒的感染.乙型肝炎病毒D型肝炎药理动力学是药理动力学的一个方面.药物动力学药物动力学

更多相关视频

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

相关概念视频

Factors Affecting Protein-Drug Binding: Drug Interactions

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...

Protein-Drug Binding: Mechanism and Kinetics

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Drug Biotransformation: Overview

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...